Research activity information

• 2014 日本リウマチ財団, リウマチ性疾患調査・研究発表に対する助成

• ANCA関連血管炎における,リツキシマブによる血小板減少症に関する後方視的検討

  吉田 知宏, 西村 啓佑, 脇 大輔, 村部 浩之

  (一社)日本臨床免疫学会, Aug. 2024, 日本臨床免疫学会総会プログラム・抄録集, 52回, 101 - 101, Japanese


• Subarachnoid Hemorrhaging with Multiple Cerebral Artery Stenoses after Initiating Remission Induction Therapy for Eosinophilic Granulomatosis with Polyangiitis: a Case Report.

  Haruka Yasuba, Hirotaka Yamada, Masaya Togo, Kento Matoba, Eriko Yamamoto Kashihara, Keisuke Nishimura, Sho Sendo, Yo Ueda, Jun Saegusa

  We encountered a 64-year-old Japanese woman who developed subarachnoid hemorrhaging (SAH) with multiple cerebral artery stenoses during remission induction therapy for eosinophilic granulomatosis and polyangiitis (EGPA). The treatment involved intensified steroid pulse therapy and continued intravenous cyclophosphamide pulse therapy, which led to beneficial effects. Given the rarity of multiple EGPA-associated cerebral artery stenoses and SAH, it is crucial to differentiate them from other diseases. The mortality rate of EGPA complicated by intracranial hemorrhagic lesions, including SAH, is high. When headache is present at the onset of EGPA, the possibility of SAH must be considered.

  May 2024, Internal medicine (Tokyo, Japan), English, Domestic magazine

  Scientific journal


• ステロイドおよびタクロリムスで寛解に至った、抗MDA-5抗体陽性の間質性肺炎合併若年性皮膚筋炎の一例

  吉田 知宏, 西村 啓佑, 脇 大輔, 村部 浩之, 横田 敏彦

  (一社)日本臨床免疫学会, Oct. 2022, 日本臨床免疫学会総会プログラム・抄録集, 50回, 101 - 101, Japanese


• Clinical Images: Giant mass on the forehead in Kimura disease.

  Tomohiro Yoshida, Keisuke Nishimura, Daisuke Waki, Nozomi Tanaka, Hiroyuki Murabe, Toshihiko Yokota

  Feb. 2022, ACR open rheumatology, English, International magazine

  Scientific journal


• Black-blood magnetic resonance imaging suggesting central nervous system vasculitis in moyamoya syndrome associated with systemic lupus erythematosus.

  Keiichiro Kadoba, Keisuke Nishimura, Daisuke Waki, Tsutomu Okada, Takao Kumazawa, Rintaro Saito, Hiroyuki Murabe, Toshihiko Yokota

  Moyamoya syndrome is a cerebrovascular disorder characterized by bilateral stenosis and occlusion of the internal carotid arteries and their branches. A 45-year-old woman with a history of systemic lupus erythematosus was admitted for recurrent ischemic strokes. Magnetic resonance (MR) angiography revealed moyamoya-like vasculopathy. Black-blood gadolinium-based contrast-enhanced MR images showed strong, concentric enhancement along the occluded arteries, which suggested vasculitis as the etiology of moyamoya-like vasculopathy. Intensive immunosuppressive therapy combined with anticoagulation therapy and rehabilitation led to a favorable outcome in this case. Black-blood MR imaging can be a non-invasive and prompt imaging modality when central nervous system vasculitis is suspected.

  Dec. 2021, Immunological medicine, 44(4) (4), 270 - 273, English, International magazine

  Scientific journal


• Annual variation rate of KL-6 for predicting acute exacerbation in patients with rheumatoid arthritis-associated interstitial lung disease.

  Nozomi Tanaka, Keisuke Nishimura, Daisuke Waki, Keiichiro Kadoba, Hiroyuki Murabe, Toshihiko Yokota

  OBJECTIVES: This study evaluated the prognostic factors for acute exacerbation (AE), including sequential changes in Krebs von den Lungen-6 (KL-6) levels, in rheumatoid arthritis-associated interstitial lung disease (RA-ILD) patients. METHODS: This was a retrospective observational study. We reviewed 125 patients diagnosed with RA-ILD between 2010 and 2019. We defined ΔKL-6 as the annual variation rate of KL-6 one visit before AE onset (or the last visit). The Cox regression analysis was used for evaluating significant variables associated with AE. We analysed the overall survival and respiratory-related death-free survival. RESULTS: Thirty-three patients (26.4%) developed AE during the observation period. The univariate analysis revealed that KL-6 levels at RA-ILD diagnosis [hazard ratio (HR), 1.11; 95% confidence interval (CI), 1.05-1.15; p < .01) and ΔKL-6 (HR: 3.69; 95% CI: -1.36 to 7.96; p = .01] were significantly associated with AE. ΔKL-6 was an independent prognostic factor for AE in the multivariate analysis (HR: 3.37; 95% CI: -1.16 to 8.87; p = .03). Patients with AE had a significantly higher overall mortality rate (p = .02) and respiratory-related mortality rate (p < .01) than those without AE. CONCLUSION: ΔKL-6 can be a prognostic marker for detecting AE in RA-ILD patients.

  Nov. 2021, Modern rheumatology, 31(6) (6), 1100 - 1106, English, International magazine

  Scientific journal


• HLA-B52 allele in giant cell arteritis may indicate diffuse large-vessel vasculitis formation: a retrospective study.

  Kazuo Kushimoto, Masahiro Ayano, Keisuke Nishimura, Miki Nakano, Yasutaka Kimoto, Hiroki Mitoma, Nobuyuki Ono, Yojiro Arinobu, Koichi Akashi, Takahiko Horiuchi, Hiroaki Niiro

  BACKGROUND: This study aimed to identify new characteristics of elderly onset large-vessel vasculitis (EOLVV) by focusing on human leucocyte antigen (HLA) genotype, polymyalgia rheumatica (PMR), and affected vascular lesions observed on positron emission tomography/computed tomography (PET/CT) imaging. METHODS: We retrospectively studied 65 consecutive Japanese patients with large-vessel vasculitis (LVV) who had extracranial vasculitis lesions and underwent PET/CT imaging. PET/CT images were assessed using the semi-quantitative PET visual score of each affected vessel, and the PET vascular activity score (PETVAS) and number of affected vessels were calculated. Subjects were subsequently grouped based on age at onset, superficial temporal artery (STA) involvement, and presence of PMR and compared each group according to HLA genotype. Unsupervised hierarchical cluster analysis was used to identify the patients with similar characteristics in terms of affected vascular lesions detected through PET/CT imaging. The clinical characteristics and PET/CT findings of the population newly identified in this study were examined. RESULTS: Twenty-seven patients with EOLVV did not meet the American College of Rheumatology 1990 criteria for giant cell arteritis (GCA) and Takayasu arteritis and were considered as unclassified EOLVV (UEOLVV). The unsupervised hierarchical cluster analysis revealed that UEOLVV with PMR and large-vessel GCA (LV-GCA) formed a cluster of LVV with GCA features (i.e., PMR and/or STA involvement) when restricted to patients who were HLA-B52-positive. Patients who were HLA-B52-positive with LVV and GCA features had similar clinical characteristics and patterns of affected vessels and presented with diffuse LVV lesions. HLA-B52-positive patients who had LVV with GCA features also presented with higher PETVAS, more affected vessels, and lower rates of biologics usage and relapse compared to HLA-B52-positive patients with TAK. CONCLUSIONS: Patients who had UEOLVV with PMR had similar characteristics to patients with LV-GCA. Patients who were HLA-B52-positive and had LVV with GCA features presented with diffuse vascular lesions and may comprise a core population of Japanese patients with EOLVV. The findings of HLA-B52 positivity and diffusely affected vessels in patients with EOLVV can be considered as suspicious findings of LV-GCA.

  Sep. 2021, Arthritis research & therapy, 23(1) (1), 238 - 238, English, International magazine

  Scientific journal


• Age-related Epstein-Barr Virus-associated Lymphoproliferative Disorder Masquerading as Systemic Lupus Erythematosus.

  Keiichiro Kadoba, Keisuke Nishimura, Kaori Uchino, Daisuke Waki, Hiroyuki Murabe, Toshihiko Yokota

  Age-related Epstein-Barr virus (EBV)-positive B-cell lymphoproliferative disorder (LPD) occurs in elderly patients without immunodeficiency. An 81-year-old woman without any known immunodeficiency was examined for fever, rash, arthritis, thrombocytopenia, pleural and pericardial effusions, lymphadenopathy, and positive autoantibodies, which satisfied the classification criteria for systemic lupus erythematosus (SLE). However, a lymph node biopsy revealed EBV-LPD, and she was diagnosed with age-related EBV-LPD. In young individuals, EBV infection is a major differential diagnosis of SLE, but to our knowledge, this is the first reported case of age-related EBV-LPD mimicking SLE. We should therefore consider EBV-related disorders in the differential diagnosis of SLE even in elderly individuals.

  Aug. 2021, Internal medicine (Tokyo, Japan), 60(15) (15), 2495 - 2497, English, Domestic magazine

  Scientific journal


• Rapid Flow Cytometry-Based Assay for the Functional Classification of MEFV Variants.

  Yoshitaka Honda, Yukako Maeda, Kazushi Izawa, Takeshi Shiba, Takayuki Tanaka, Haruna Nakaseko, Keisuke Nishimura, Hiroki Mukoyama, Masahiko Isa-Nishitani, Takayuki Miyamoto, Hiroshi Nihira, Hirofumi Shibata, Eitaro Hiejima, Osamu Ohara, Junko Takita, Takahiro Yasumi, Ryuta Nishikomori

  PURPOSE: Pathogenic MEFV variants cause pyrin-associated autoinflammatory diseases (PAADs), which include familial Mediterranean fever (FMF), FMF-like disease, and pyrin-associated autoinflammation with neutrophilic dermatosis (PAAND). The diagnosis of PAADs is established by clinical phenotypic and genetic analyses. However, the pathogenicity of most MEFV variants remains controversial, as they have not been functionally evaluated. This study aimed to establish and validate a new functional assay to evaluate the pathogenicity of MEFV variants. METHODS: We transfected THP-1 monocytes with 32 MEFV variants and analyzed their effects on cell death with or without stimulation with Clostridium difficile toxin A (TcdA) or UCN-01. These variants were classified using hierarchical cluster analysis. Macrophages were obtained from three healthy controls and two patients with a novel homozygous MEFVP257L variant, for comparison of IL-1β secretion using a cell-based assay and a novel THP-1-based assay. RESULTS: Disease-associated MEFV variants induced variable degrees of spontaneous or TcdA/UCN-01-induced cell death in THP-1. Cell death was caspase-1 dependent and was accompanied by ASC speck formation and IL-1β secretion, indicating that pathogenic MEFV variants induced abnormal pyrin inflammasome activation and subsequent pyroptotic cell deaths in this assay. The MEFV variants (n = 32) exhibiting distinct response signatures were classified into 6 clusters, which showed a good correlation with the clinical phenotypes. Regarding the pathogenicity of MEFVP257L variants, the results were consistent between the cell-based assay and the THP-1-based assay. CONCLUSION: Our assay facilitates a rapid and comprehensive assessment of the pathogenicity of MEFV variants and contributes to a refined definition of PAAD subtypes.

  Aug. 2021, Journal of clinical immunology, 41(6) (6), 1187 - 1197, English, International magazine

  Scientific journal


• Clinical features and pathology of respiratory failure due to inflammatory myopathy induced by immune checkpoint inhibitors.

  Yuriko Aratake, Kaoru Obata, Keisuke Nishimura, Katsuro Shindo

  Jun. 2021, Clinical and experimental rheumatology, English, International magazine


• Protective effect of different doses of trimethoprim-sulfamethoxazole prophylaxis for early severe infections among patients with antineutrophil cytoplasmic autoantibody-associated vasculitis

  Daisuke Waki, Keisuke Nishimura, Tomohiro Yoshida, Nozomi Tanaka, Kaoru Mizukawa, Mayuko Fukushima, Osamu Iri, Motoko Anegawa, Hiroyuki Murabe, Toshihiko Yokota

  Clinical and Experimental Rheumatology, May 2021, Clinical and Experimental Rheumatology, 39(2) (2), 142 - 148

  Scientific journal


• Impact of the Combined Immunosuppressive Therapy on Different Mortality Score Groups in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease and the Problem of Sample Splitting.

  Daisuke Waki, Keisuke Nishimura

  Feb. 2021, Chest, 159(2) (2), 882 - 883, English, International magazine


• Mycophenolate Mofetil-induced Diffuse Large B-cell Lymphoma in Which a Solitary Lung Nodule Remitted Spontaneously.

  Hiroshi Kobe, Akihiro Ito, Hiroki Hayata, Keisuke Nishimura, Yasunori Ueda, Tadashi Ishida

  A 76-year-old woman with dermatomyositis was being treated with prednisolone, tacrolimus, and mycophenolate mofetil. There was a solitary lung nodule in the right middle lobe on chest computed tomography at a routine follow-up examination. A transbronchial lung biopsy was performed, and the histopathologic findings indicated diffuse large B-cell lymphoma. An immunodeficiency-associated lymphoproliferative disorder was suspected, and mycophenolate mofetil was stopped without adding any other therapy. Nine months later, the pulmonary nodule had disappeared on chest computed tomography.

  Jan. 2021, Internal medicine (Tokyo, Japan), 60(1) (1), 131 - 136, English, Domestic magazine

  Scientific journal


• Development of severe thrombocytopenia with TAFRO syndrome-like features in a patient with rheumatoid arthritis treated with a Janus kinase inhibitor: A case report.

  Keiichiro Kadoba, Daisuke Waki, Keisuke Nishimura, Hiroki Mukoyama, Rintaro Saito, Hiroyuki Murabe, Toshihiko Yokota

  RATIONALE: Thrombocytepenia, anasarca, fever, renal insufficiency, and organomegaly (TAFRO) syndrome is a novel disease entity characterized by a constellation of symptoms (thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly). Here, we describe the development of TAFRO syndrome-like features during the treatment of rheumatoid arthritis with a Janus kinase (JAK) inhibitor. PATIENT CONCERNS: In this report, a 74-year-old woman treated with a JAK inhibitor (tofacitinib) for rheumatoid arthritis was admitted because of fever and thrombocytopenia. DIAGNOSES: On laboratory examination, marked thrombocytopenia and elevated creatinine and C-reactive protein levels were present. A computed tomography scan revealed lymphadenopathy, hepato-splenomegaly, and anasarca. A left axillary lymph node biopsy revealed Castleman's disease-like features. These clinical features satisfied the proposed diagnostic criteria for TAFRO syndrome. Since autoimmune disorders should be excluded when diagnosing TAFRO syndrome, it is not strictly correct to diagnose her as TAFRO syndrome. Therefore, we diagnosed her as rheumatoid arthritis complicated by TAFRO syndrome-like features. INTERVENTIONS: The patient was treated with high-dose glucocorticoid, tacrolimus, eltrombopag, intravenous immunoglobulin, and rituximab. OUTCOMES: Her condition was refractory to the above-mentioned treatment, and she eventually died because of multi-organ failure 6 months after the first admission. LESSONS: TAFRO syndrome-like features can develop during treatment with a JAK inhibitor for rheumatoid arthritis. Patients with autoimmune diseases complicated by TAFRO syndrome-like features can follow a fatal clinical course, and thus, an intensive combined treatment is warranted for such patients, especially in cases refractory to glucocorticoid.

  Oct. 2020, Medicine, 99(42) (42), e22793, English, International magazine

  Scientific journal


• Therapeutic plasma exchange for clinically amyopathic dermatomyositis (CADM) associated with rapidly progressive interstitial pneumonia.

  Akira Yamagata, Machiko Arita, Ayaka Tanaka, Fumiaki Tokioka, Tomohiro Yoshida, Keisuke Nishimura, Tadashi Ishida

  BACKGROUND: Patients with clinically amyopathic dermatomyositis (CADM) with anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5 Ab) frequently develop rapidly progressive interstitial pneumonia (RPIP), often with fatal outcomes. Therapeutic plasma exchange (TPE) has been reported as effective against CADM-RPIP refractory to conventional immunosuppressive therapy. However, the detailed mechanisms by which TPE improves disease activity of CADM-RPIP remain unclear. AIM: To elucidate the clinical and demographic characteristics of patients with anti-MDA5 Ab-positive CADM-RPIP treated with TPE and to analyze changes in laboratory findings before, during, and after TPE. MATERIALS & METHODS: Patients hospitalized for CADM-RPIP and treated with TPE in 2017 and 2018 were analyzed retrospectively. RESULTS: Three patients were successfully treated with TPE, with good tolerance. Anti-MDA5 Ab titers decreased significantly over the course of TPE. CONCLUSION: We emphasize that TPE could represent an effective treatment option for CADM-RPIP refractory to traditional therapy. Removal of anti-MDA5 Ab and other pathogenic factors may facilitate favorable outcomes.

  Sep. 2020, Journal of clinical apheresis, 35(5) (5), 435 - 443, English, International magazine

  Scientific journal


• Shoulder ultrasound and serum lactate dehydrogenase predict inadequate response to glucocorticoid treatment in patients with polymyalgia rheumatica.

  Masahiro Ayano, Yojiro Arinobu, Hiroshi Tsukamoto, Shun-Ichiro Ota, Kenta Misaki, Keisuke Nishimura, Yasutaka Kimoto, Hiroki Mitoma, Mitsuteru Akahoshi, Koichi Akashi, Takahiko Horiuchi, Hiroaki Niiro

  We aimed to identify predictors of inadequate response to glucocorticoid (GC) treatment in patients with polymyalgia rheumatica (PMR). We retrospectively studied 32 patients as a derivation cohort and 24 patients as a validation cohort. The patients were divided into two groups according to the response to GC treatment: GC-responders and GC-inadequate responders (GC-IRs). We compared laboratory data and bilateral shoulder ultrasound findings between the groups. Receiver operating characteristic (ROC) analysis was performed to determine the optimal cutoff value of candidate predictors of treatment response; the predictors were examined using multivariate logistic analysis. Gray-scale ultrasound findings of long head of the biceps (LHB) tenosynovitis and subacromial/subdeltoid (SAD) bursitis were scored semiquantitatively (0-3). A total gray-scale score (TGSS) was calculated as the sum of the gray-scale scores. In the derivation cohort, serum lactate dehydrogenase (LDH) levels and TGSS were significantly higher in GC-IRs than in GC-responders. On ROC analysis, the cutoff values of serum LDH levels ≥ 175 IU/ml and TGSS ≥ 5 were found to be the candidate predictors. Multivariate logistic analysis revealed an independent association of both the predictors with inadequate response to GC treatment. In the validation cohort, patients with one or both predictors exhibited a higher incidence of inadequate response to GC treatment. These findings indicate that the severities of LHB tenosynovitis and SAD bursitis evaluated using ultrasound and serum LDH levels are independent predictors of inadequate response to GC treatment in patients with PMR. Treatment adjustment based on prediction model may allow precise treatment of patients with PMR.

  Jul. 2020, Rheumatology international, 40(7) (7), 1101 - 1109, English, International magazine

  Scientific journal


• Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: A retrospective observational study.

  Daisuke Waki, Keisuke Nishimura, Hironobu Tokumasu, Keiichiro Kadoba, Hiroki Mukoyama, Rintaro Saito, Hiroyuki Murabe, Toshihiko Yokota

  Recent large observational studies of antineutrophil cytoplasmic autoantibody-associated vasculitis (AAV) show that severe infection is a major cause of death and that the majority of infections occur during the early phase of initiating remission-induction therapy. Many risk factors for severe infection have been suggested, but these have been inconsistent. Nevertheless, infectious risk factors in elderly patients with AAV have not been adequately investigated in previous studies.In this retrospective observational study, we examined potential predictors of severe infection within 90 days (early severe infections) after remission-induction therapy in patients with AAV aged 65 years or older. We included 167 consecutive elderly patients with AAV admitted to our hospital. Data from medical history and remission-induction therapy were analyzed for predictive risk factors associated with early severe infections. The relationship between initial doses of corticosteroids and cumulative incidence of severe infections was also analyzed. A multivariate analysis of risk factors for early severe infections was performed using logistic regression analysis. The Kaplan-Meier method was used to estimate the overall survival, and the log-rank test was used to evaluate the differences between patients with and without early severe infections. Gray method was used to compare the cumulative incidence of severe infections in patients who did and did not receive initial high-dose corticosteroids.Logistic regression analysis showed that initial high-dose corticosteroid administration (prednisolone ≥0.8 mg/kg/d) (odds ratio [OR] 3.86, P = .030) and serum creatinine levels at diagnosis ≥1.5 mg/dL (OR 5.13, P = .003) were independent predictors of early severe infection although administration of cyclophosphamide or rituximab was not. The cumulative incidence of severe infections was also significantly higher in patients who received initial high-dose corticosteroids (P = .042), and patients with early severe infections exhibited a high mortality rate within 6 months (P < .001).Our findings suggest that initial high-dose corticosteroids and renal impairment at diagnosis are associated with a higher risk of early severe infections and early death in elderly patients with AAV.

  Feb. 2020, Medicine, 99(8) (8), e19173, English, International magazine

  Scientific journal


• Cutaneous diffuse large B-cell lymphoma mimicking rheumatoid vasculitis.

  Daisuke Waki, Keisuke Nishimura, Keiichiro Kadoba, Toshihiko Yokota

  Jan. 2020, Rheumatology (Oxford, England), 59(1) (1), 263 - 263, English, International magazine

  Scientific journal


• Large vessel giant cell arteritis suggested by magnetic resonance imaging of the thigh: a potential mimicker of myositis, fasciitis and skeletal muscle vasculitis.

  Keiichiro Kadoba, Kaoru Mizukawa, Keisuke Nishimura, Hiroyuki Murabe

  Dec. 2019, Rheumatology (Oxford, England), 58(12) (12), 2211 - 2211, English, International magazine

  Scientific journal


• Subjective well-being among rheumatoid arthritis patients.

  Goichi Kageyama, Akira Onishi, Yo Ueda, Ikuko Naka, Kosaku Tsuda, Takaichi Okano, Kengo Akashi, Keisuke Nishimura, Sho Sendo, Jun Saegusa, Akio Morinobu

  AIM: Subjective well-being (SWB) is a psychological construct that is synonymous with happiness. Many variables including age, sex, income, employment, and marital status are related to SWB. Health is also an important determinant of SWB that can be adversely affected in patients with chronic conditions such as rheumatoid arthritis (RA). In this study, we evaluate the SWB of RA patients and compare it with that of healthy controls. METHODS: We obtained the original dataset from the "Quality of Life Survey, 2013", which was conducted by the Economic and Social Research Institute, Cabinet Office, Government of Japan. In this survey, SWB was determined by asking participants to rate their happiness between 0 (very unhappy) and 10 (very happy). The survey also included a 56-point questionnaire regarding well-being-related variables. This questionnaire was administered to RA patients recruited from Kobe University Hospital, and clinical and treatment data were simultaneously collected. RESULTS: Multivariate analysis revealed that RA patients with high or moderate disease activity had SWB scores that were similar to those of controls. However, the SWB scores of RA patients in remission or with low disease activity were higher than those of controls (P = .013). SWB was associated with household income, self-assessment of living costs, self-assessment of health, depression/ anxiety, and social connection. CONCLUSIONS: For RA patients, achieving the therapeutic target can result in better SWB than that of healthy controls. Financial status, self-assessment of health, psychological stress, and social network are also important determinants for the SWB of RA patients.

  Oct. 2019, International journal of rheumatic diseases, 22(10) (10), 1863 - 1870, English, International magazine

  [Refereed]

  Scientific journal


• Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice.

  Sho Sendo, Jun Saegusa, Hirotaka Yamada, Keisuke Nishimura, Akio Morinobu

  BACKGROUND: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a sometimes life-threatening complication in RA patients. SKG mice develop not only arthritis but also an ILD resembling RA-ILD. We previously reported that tofacitinib, a JAK inhibitor, facilitates the expansion of myeloid-derived suppressor cells (MDSCs) and ameliorates arthritis in SKG mice. The aim of this study was to elucidate the effect of tofacitinib on the ILD in SKG mice. METHODS: We assessed the effect of tofacitinib on the zymosan (Zym)-induced ILD in SKG mice histologically and examined the cells infiltrating the lung by flow cytometry. The effects of lung MDSCs on T cell proliferation and Th17 cell differentiation were assessed in vitro. We also evaluated the effects of tofacitinib on MDSCs and dendritic cells in vitro. RESULTS: Tofacitinib significantly suppressed the progression of ILD compared to the control SKG mice. The MDSCs were increased, while Th17 cells, group 1 innate lymphoid cells (ILC1s), and GM-CSF+ILCs were decreased in the lungs of tofacitinib-treated mice. MDSCs isolated from the inflamed lungs suppressed T cell proliferation and Th17 cell differentiation in vitro. Tofacitinib promoted MDSC expansion and suppressed bone marrow-derived dendritic cell (BMDC) differentiation in vitro. CONCLUSION: Tofacitinib facilitates the expansion of MDSCs in the lung and ameliorates ILD in SKG mice.

  Aug. 2019, Arthritis research & therapy, 21(1) (1), 184 - 184, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• THU0592 PREDICTORS OF RELAPSE OF IGG4-RELATED DISEASE AFTER INDUCTION THERAPY: A RETROSPECTIVE STUDY

  Tomohiro Yoshida, Keisuke Nishimura, Kaoru Mizukawa, Keiichiro Kadoba, Hiroki Mukoyama, Daisuke Waki, Toshihiko Yokota, Hiroyuki Murabe

  BMJ Publishing Group Ltd and European League Against Rheumatism, Jun. 2019, Poster Presentations

  International conference proceedings


• Efficacy of Plasma Exchange in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.

  Keisuke Nishimura, Daisuke Waki, Keiichiro Kadoba, Hiroki Mukoyama, Toshihiko Yokota, Hiroyuki Murabe

  We aimed to investigate the efficacy of plasma exchange on severe anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Of 182 patients with AAV in our hospital, 12 patients with life-threatening organ damage (rapidly progressive glomerulonephritis and/or diffuse alveolar hemorrhage) underwent centrifuge-based therapeutic plasma exchange and immunosuppressive therapy. Twenty-four patients matched for age, serum creatinine, and severity of vasculitis, who received high-dose glucocorticoids with or without immunosuppressants, were included in the nonplasma exchange group. Renal survival rate at 2 years from induction treatment was not significantly different between the plasma and nonplasma exchange groups (P = 0.524). Mortality rate at 5 years from induction treatment was not significantly different between the plasma and nonplasma exchange groups (P = 0.631). In this retrospective study, we could not show the significant differences in the renal survival rate and survival rate between the two groups.

  Jun. 2019, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 23(3) (3), 248 - 252, English, International magazine

  Scientific journal


• Additive effects of inhibiting both mTOR and glutamine metabolism on the arthritis in SKG mice.

  Yo Ueda, Jun Saegusa, Takaichi Okano, Sho Sendo, Hirotaka Yamada, Keisuke Nishimura, Akio Morinobu

  Glutamine metabolism and the mechanistic target of rapamycin (mTOR) pathway are activated cooperatively in the differentiation and activation of inflammatory immune cells. But the combined inhibition of both pathways was rarely investigated. This study investigated how inhibiting both glutamine metabolism with 6-diazo-5-oxo-L-norleucine (DON) and mTOR with rapamycin affects immune cells and the arthritis in a mouse model. We revealed that rapamycin and DON additively suppressed CD4+ T cell proliferation, and both of them inhibited Th17 cell differentiation. While DON inhibited the differentiation of dendritic cells and macrophages and facilitated that of Ly6G+ granulocytic (G)-MDSCs more strongly than did rapamycin, G-MDSCs treated with rapamycin but not DON suppressed CD4+ T cell proliferation in vitro. The combination of rapamycin and DON significantly suppressed the arthritis in SKG mice more strongly than did each monotherapy in vivo. The numbers of CD4+ T and Th17 cells in the spleen were lowest in mice treated with the combination therapy. Thus, combined treatment with rapamycin and DON additively ameliorated the arthritis in SKG mice, possibly by suppressing CD4+ T cell proliferation and Th17 differentiation. These results suggest the combination of rapamycin and DON may be a potential novel therapy for arthritis.

  Apr. 2019, Scientific reports, 9(1) (1), 6374 - 6374, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Radiological fibrosis score is strongly associated with worse survival in rheumatoid arthritis-related interstitial lung disease.

  Yuhei Ito, Machiko Arita, Shogo Kumagai, Reoto Takei, Maki Noyama, Fumiaki Tokioka, Keisuke Nishimura, Takashi Koyama, Hiromasa Tachibana, Tadashi Ishida

  OBJECTIVES: High-resolution computed tomography (HRCT) parenchymal patterns have been used to predict prognosis in patients with interstitial lung disease (ILD). In idiopathic pulmonary fibrosis, the fibrosis score (i.e. the combined extent of reticulation and honeycombing) has been associated with worse survival. This study aimed to identify HRCT patterns and patient characteristics that can predict poor prognosis in rheumatoid arthritis-related ILD (RA-ILD). METHODS: We retrospectively analysed 65 patients with newly diagnosed RA-ILD from 2007 to 2016 at Kurashiki Central hospital. Using univariate and bivariate Cox regression analysis, associations with mortality, were identified. RESULTS: During a median follow-up of 56.5 months, 16/65 (24.6%) patients died. Univariate analysis identified six significant poor prognostic factors: lower baseline % predicted forced vital capacity, total interstitial disease score, reticulation score, traction bronchiectasis score, fibrosis score, and definite UIP pattern. Fibrosis score remained to be an independently significant poor prognostic factor of survival on bivariate analysis. Patients with a fibrosis score >20% had higher mortality (HR, 9.019; 95% CI, 2.87-28.35; p < .05). CONCLUSION: This study showed that fibrosis score is strongly associated with worse survival in RA-ILD, and patients with fibrosis score >20% had a 9.019-fold increased risk of mortality.

  Jan. 2019, Modern rheumatology, 29(1) (1), 98 - 104, English, International magazine

  Scientific journal


• Radiographic fibrosis score predicts survival in systemic sclerosis-associated interstitial lung disease.

  Reoto Takei, Machiko Arita, Shogo Kumagai, Yuhei Ito, Fumiaki Tokioka, Takashi Koyama, Rintaro Saito, Keisuke Nishimura, Hironobu Tokumasu, Tadashi Ishida

  BACKGROUND AND OBJECTIVE: Interstitial lung disease (ILD) is a common pulmonary manifestation of systemic sclerosis (SSc). It is unknown whether radiographic fibrosis score predicts mortality in SSc-associated ILD (SSc-ILD). We retrospectively analysed patients with SSc-ILD to evaluate whether radiographic fibrosis score was a useful predictor of mortality. METHODS: We identified SSc-ILD patients evaluated at Kurashiki Central Hospital (Japan) from 2006 to 2016, and radiographic fibrosis scores based on the extent of reticulation and honeycombing on high-resolution computed tomography (HRCT) scanning were calculated by manually tracing around each fibrotic area. Independent predictors of overall survival were determined using the Cox proportional hazards model. RESULTS: The study included 48 patients, of whom 19 had usual interstitial pneumonia on HRCT. The median follow-up period was 56.6 months, and over the follow-up period 15 patients died. The 5-year survival was 72.4%. In the multivariate analysis, radiographic fibrosis score, age, being male and forced vital capacity were independently associated with an increased risk of death, while HRCT pattern was not. CONCLUSION: A high radiographic fibrosis score was a poor prognostic factor in SSc-ILD. More widespread fibrosis was associated with an increased risk of death, independent of HRCT pattern.

  Apr. 2018, Respirology (Carlton, Vic.), 23(4) (4), 385 - 391, English, International magazine

  Scientific journal


• Serological and morphological prognostic factors in patients with interstitial pneumonia with autoimmune features.

  Yuhei Ito, Machiko Arita, Shogo Kumagai, Reoto Takei, Maki Noyama, Fumiaki Tokioka, Keisuke Nishimura, Takashi Koyama, Kenji Notohara, Tadashi Ishida

  BACKGROUND: To identify the prognostic factors for survival in patients with interstitial pneumonia with autoimmune features (IPAF) who meet the serological domain of the IPAF criteria. METHODS: We retrospectively analysed 99 IPAF patients who met the serological domain and were hospitalised at the Respiratory Medicine Unit of Kurashiki Central Hospital from 1999 to 2015. The high-resolution computed tomography findings were usual interstitial pneumonia (UIP; n = 1), non-specific interstitial pneumonia (NSIP; n = 63), NSIP with organizing pneumonia (OP) overlap (n = 15), and OP (n = 20). One patient who had radiological UIP pattern, and met the serological and clinical domains was excluded. The clinical characteristics, radiological findings, administered therapy, and prognosis of the remaining 98 IPAF patients who met the serological and morphological domains were analysed. RESULTS: The median age of the 98 IPAF patients was 68 years, and 41 (41.8%) of them were men. Twelve (12.2%) of the 98 IPAF patients developed other characteristics and were diagnosed with connective tissue disease (CTD) later during the median follow-up of 4.5 years. Univariate Cox analysis revealed systemic sclerosis (SSc)-specific and SSc-associated antibodies (ANA nucleolar pattern, ANA centromere pattern, anti-ribonucleoprotein and anti-Scl-70) positive IPAF, radiological NSIP pattern, bronchoalveolar lavage fluid lymphocytes >15%, and age as significant prognostic factors for survival. Multivariate Cox analysis revealed radiological NSIP pattern (hazard ratio [HR], 4.48; 95% confidence interval [CI], 1.28-15.77, p = 0.02) and age (HR, 1.07; 95% CI, 1.02-1.11, p = 0.01) were significantly associated with worse survival. CONCLUSIONS: We confirmed that radiological NSIP pattern and age are poor prognostic factors for the survival of IPAF patients. This study suggested that the autoantibodies that are highly specific for certain connective tissue diseases might be less important for the prognosis of IPAF compared with the radiological-pathological patterns. The relatively high proportion of IPAF patients who developed CTD later suggests the importance of careful observation for evolution to CTD in IPAF.

  Aug. 2017, BMC pulmonary medicine, 17(1) (1), 111 - 111, English, International magazine

  Scientific journal


• Very high frequency of fragility fractures associated with high-dose glucocorticoids in postmenopausal women: A retrospective study.

  Goichi Kageyama, Takaichi Okano, Yuzuru Yamamoto, Keisuke Nishimura, Daisuke Sugiyama, Jun Saegusa, Goh Tsuji, Shunichi Kumagai, Akio Morinobu

  Purpose To evaluate the incidence of fragility fractures associated with high-dose glucocorticoid therapy in patients with systemic rheumatic disease. METHODS: A retrospective study of patients who were treated with high-dose prednisolone (> 0.8 mg/kg) for systemic rheumatic disease at Kobe University Hospital from April 1988 to March 2012. The primary outcome was a major osteoporotic fracture (defined as a clinical vertebral, hip, forearm, or proximal humerus fracture) after high-dose glucocorticoid therapy. For postmenopausal women and men over 40 of age, the patient's fracture risk at the beginning of high-dose glucocorticoid therapy was assessed by the World Health Organization's Fracture Risk Assessment Tool (FRAX®). Results Of 229 patients (median age: 49 years), 57 suffered a fragility fracture during the observation period (median observation period: 1558 days). Of 84 premenopausal patients, 5 suffered a fracture. In contrast, of 86 postmenopausal female, 36 suffered a fracture. Fragility fractures were far more frequent than predicted by the FRAX® score. Patients with FRAX® scores over 8.3% had a particularly high risk of fracture. Conclusions Fragility fractures associated with high-dose glucocorticoid therapy are common among postmenopausal women. Extreme care should be taken especially for postmenopausal women when high-dose glucocorticoid therapy is required.

  Jun. 2017, Bone reports, 6, 3 - 8, English, International magazine

  Scientific journal


• 3-bromopyruvate ameliorate autoimmune arthritis by modulating Th17/Treg cell differentiation and suppressing dendritic cell activation

  Takaichi Okano, Jun Saegusa, Keisuke Nishimura, Soshi Takahashi, Sho Sendo, Yo Ueda, Akio Morinobu

  Feb. 2017, SCIENTIFIC REPORTS, 7, 42412, English

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Expression and Functions of Immediate Early Response Gene X-1 (IEX-1) in Rheumatoid Arthritis Synovial Fibroblasts

  Akio Morinobu, Shino Tanaka, Keisuke Nishimura, Soshi Takahashi, Goichi Kageyama, Yasushi Miura, Masahiro Kurosaka, Jun Saegusa, Shunichi Kumagai

  Oct. 2016, PLOS ONE, 11(10) (10), e0164350, English

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Knockout of endothelin type B receptor signaling attenuates bleomycin-induced skin sclerosis in mice

  Kengo Akashi, Jun Saegusa, Sho Sendo, Keisuke Nishimura, Takuya Okano, Keiko Yagi, Masashi Yanagisawa, Noriaki Emoto, Akio Morinobu

  May 2016, ARTHRITIS RESEARCH & THERAPY, 18(1) (1), 113, English

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates arthritis in SKG mice.

  Keisuke Nishimura, Jun Saegusa, Fumichika Matsuki, Kengo Akashi, Goichi Kageyama, Akio Morinobu

  OBJECTIVE: Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells that have the ability to suppress T cell responses. The aim of this study was to evaluate the effects of the JAK inhibitor tofacitinib on MDSCs in a mouse model of rheumatoid arthritis. METHODS: Arthritis was induced in SKG mice by zymosan A (ZyA) injection. MDSCs isolated from the bone marrow (BM) of donor SKG mice with arthritis were adoptively transferred to recipient mice with arthritis. In a separate experiment, tofacitinib was administered to arthritic SKG mice subcutaneously via osmotic pump, in some cases followed by injection of an anti-Gr-1 monoclonal antibody (mAb). BM cells from untreated mice were cultured for 5 days with granulocyte-macrophage colony-stimulating factor, with or without tofacitinib, and then analyzed by flow cytometry. RESULTS: The numbers of MDSCs and polymorphonuclear MDSCs (PMN-MDSCs) were significantly increased in the spleens of SKG mice following ZyA injection. Adoptive transfer of MDSCs to recipient arthritic mice reduced the severity of arthritis compared to that in untreated control mice. Treatment with tofacitinib also ameliorated the progression of arthritis in SKG mice and induced significantly higher numbers of MDSCs and PMN-MDSCs in the BM of these animals. Furthermore, administration of an anti-Gr-1 mAb reduced the antiarthritic effect of tofacitinib in SKG mice. In vitro, tofacitinib facilitated the differentiation of BM cells to MDSCs, and inhibited their differentiation to dendritic cells. CONCLUSION: Tofacitinib facilitates the expansion of MDSCs and ameliorates arthritis in SKG mice.

  Apr. 2015, Arthritis & rheumatology (Hoboken, N.J.), 67(4) (4), 893 - 902, English, International magazine

  Scientific journal


• CD45RA-Foxp3(low) non-regulatory T cells in the CCR7-CD45RA-CD27+CD28+effector memory subset are increased in synovial fluid from patients with rheumatoid arthritis

  Fumichika Matsuki, Jun Saegusa, Keisuke Nishimura, Yasushi Miura, Masahiro Kurosaka, Shunichi Kumagai, Akio Morinobu

  Jul. 2014, CELLULAR IMMUNOLOGY, 290(1) (1), 96 - 101, English

  [Refereed]

  Scientific journal


• Mycophenolate mofetil versus intravenous cyclophosphamide for induction treatment of proliferative lupus nephritis in a Japanese population

  Onishi Akira, Sugiyama Daisuke, Tsuji Go, Nakazawa Takashi, Kogata Yoshinori, Tsuda Kosaku, Naka Ikuko, Nishimura Keisuke, Misaki Kenta, Kurimoto Chiyo, Hayashi Hiroki, Kageyama Goichi, Saegusa Jun, Sugimoto Takeshi, Kawano Seiji, Kumagai Shunichi, Morinobu Akio

  <p>Objectives: Recent studies have shown that mycophenolate mofetil (MMF) is similar to intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis (LN), but that treatment response may vary according to location and race/ethnicity. Moreover, no studies have been conducted to compare the efficacy of MMF with that of IVC for a Japanese population. We therefore conducted a retrospective study to clarify the efficacy and safety of MMF compared with that of IVC for induction therapy for active LN, classes III and IV, in a Japanese population of 21 patients, 11 of whom received MMF and 10 IVC. Methods: The primary endpoint was expressed as the percentage of responders, who in turn were defined as the patients who met complete or partial response criteria according to the European consensus statement. The secondary endpoints comprised the renal activity component and serological activity. Results: The primary endpoint was achieved in nine (81.8 %) patients receiving MMF and in four (40.0 %) receiving IVC, with no significant difference between the two groups (p = 0.081), while there was also no significant difference between them in terms of secondary endpoints. However, the

  Jan. 2013, Modern Rheumatology, 23(1) (1), 89 - 96, English


• Tumor necrosis factor-α inhibitor-induced antiglomerular basement membrane antibody disease in a patient with rheumatoid arthritis.

  Keisuke Nishimura, Jun Saegusa, Seiji Kawano, Akio Morinobu

  Sep. 2012, The Journal of rheumatology, 39(9) (9), 1904 - 5, English, International magazine

  [Refereed]


• Role of imaging studies in the diagnosis and evaluation of giant cell arteritis in Japanese: report of eight cases

  Akio Morinobu, Goh Tsuji, Shimpei Kasagi, Jun Saegusa, Hiroki Hayashi, Takashi Nakazawa, Yoshinori Kogata, Kenta Misaki, Keisuke Nishimura, Sho Sendo, Natsuko Miura, Seiji Kawano, Shunichi Kumagai

  Aug. 2011, MODERN RHEUMATOLOGY, 21(4) (4), 391 - 396, English

  [Refereed]

  Scientific journal

• 間質性肺炎と横紋筋融解症が先行した、視神経脊髄炎スペクトラム障害の一例

  吉田 知宏, 西村 啓佑, 廣瀬 啓, 井利 宰, 姉川 修子, 水川 薫, 脇 大輔, 村部 浩之, 横田 敏彦

  (一社)日本臨床免疫学会, Oct. 2021, 日本臨床免疫学会総会プログラム・抄録集, 49回, 110 - 110, Japanese


• 血管炎に対するアフェレシス療法 ANCA関連血管炎に対する血漿交換療法の意義

  西村 啓佑

  (一社)日本アフェレシス学会, Oct. 2021, 日本アフェレシス学会雑誌, 40(Suppl.) (Suppl.), 65 - 65, Japanese


• 難治性の高齢成人発症スチル病の報告 当施設における高齢成人発症スチル病の検討

  田中 望美, 西村 啓佑, 脇 大輔, 門場 啓一郎, 吉田 知宏, 村部 浩之, 横田 敏彦

  (一社)日本臨床リウマチ学会, Mar. 2021, 臨床リウマチ, 33(1) (1), 62 - 69, Japanese


• 大型血管炎:巨細胞性動脈炎 PET-CT及び臨床所見に基づいた高齢発症Large vessel vasculitis(LVV)の検討

  久志本 和郎, 綾野 雅宏, 西村 啓佑, 中野 未来, 木本 泰孝, 三苫 弘喜, 小野 伸之, 有信 洋二郎, 赤司 浩一, 堀内 孝彦, 新納 宏昭

  (一社)日本リウマチ学会, Mar. 2021, 日本リウマチ学会総会・学術集会プログラム・抄録集, 65回, 404 - 404, Japanese


• 再発性多発軟骨炎・TAFROなどの希少疾患 再発性多発軟骨炎において診断時の抗II型コラーゲン抗体陽性は再燃のリスクである

  井利 宰, 姉川 修子, 田中 望美, 福嶋 真悠子, 水川 薫, 吉田 知宏, 脇 大輔, 西村 啓佑, 村部 浩之, 横田 敏彦

  (一社)日本リウマチ学会, Mar. 2021, 日本リウマチ学会総会・学術集会プログラム・抄録集, 65回, 432 - 432, Japanese


• 自己炎症症候群 新規機能解析系によるMEFVバリアントの病原性分類

  前田 由可子, 本田 吉孝, 井澤 和司, 芝 剛, 田中 孝之, 中瀬古 春奈, 西村 啓佑, 向山 宙希, 宮本 尚幸, 伊佐 真彦[西谷], 仁平 寛士, 柴田 洋史, 八角 高裕, 西小森 隆太

  (一社)日本リウマチ学会, Mar. 2021, 日本リウマチ学会総会・学術集会プログラム・抄録集, 65回, 446 - 446, Japanese


• 末梢神経障害を呈した、成人発症の溶連菌感染関連結節性多発動脈炎の一例

  田中 望美, 門場 啓一郎, 吉田 知宏, 脇 大輔, 西村 啓佑, 村部 浩之, 横田 敏彦

  (一社)日本リウマチ学会, Mar. 2021, 日本リウマチ学会総会・学術集会プログラム・抄録集, 65回, 667 - 667, Japanese


• 木村病に対し、ステロイドと免疫抑制薬の併用が奏功した一例

  吉田 知宏, 西村 啓佑, 田中 望美, 脇 大輔, 村部 浩之, 横田 敏彦

  (一社)日本臨床免疫学会, Oct. 2020, 日本臨床免疫学会総会プログラム・抄録集, 48回, 103 - 103, Japanese


• IgG4関連疾患(臨床) IgG4関連後腹膜線維症の臨床的特徴と再燃危険因子に関する検討

  吉田 知宏, 西村 啓佑, 田中 望美, 門場 啓一郎, 脇 大輔, 村部 浩之, 横田 敏彦

  (一社)日本リウマチ学会, Aug. 2020, 日本リウマチ学会総会・学術集会プログラム・抄録集, 64回, 384 - 384, Japanese


• IgG4関連疾患(臨床) IgG4関連疾患に自己免疫性自律神経障害を合併した1例

  水川 薫, 西村 啓佑, 門場 啓一郎, 向山 宙希, 吉田 知宏, 脇 大輔, 村部 浩之, 横田 敏彦

  (一社)日本リウマチ学会, Aug. 2020, 日本リウマチ学会総会・学術集会プログラム・抄録集, 64回, 385 - 385, Japanese


• 抗リボソームP抗体陽性全身性エリテマトーデス患者の臨床的特徴に関する検討

  門場 啓一郎, 西村 啓佑, 田中 望美, 吉田 知宏, 脇 大輔, 村部 浩之, 横田 敏彦

  (一社)日本リウマチ学会, Aug. 2020, 日本リウマチ学会総会・学術集会プログラム・抄録集, 64回, 659 - 659, Japanese


• ANCA関連血管炎患者でのサイトメガロウイルスの再活性化と診断時の腎機能低下はその後の重症感染症を予測する

  脇 大輔, 西村 啓佑, 門場 啓一郎, 吉田 知宏, 田中 望美, 村部 浩之, 横田 敏彦

  (一社)日本リウマチ学会, Aug. 2020, 日本リウマチ学会総会・学術集会プログラム・抄録集, 64回, 749 - 749, Japanese


• 傍椎体病変を有する多発血管炎性肉芽腫症の1例

  姉川 修子, 吉田 知宏, 西村 啓佑, 村部 浩之, 横田 敏彦

  (公財)大原記念倉敷中央医療機構倉敷中央病院, Mar. 2020, 倉敷中央病院年報, 82, 27 - 32, Japanese


• Genetic and clinical prediction models for the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a multicenter cohort study.

  Akira Onishi, Shigeo Kamitsuji, Miwa Nishida, Yuko Uemura, Miho Takahashi, Toshiharu Saito, Yuichiro Yoshida, Masaki Kobayashi, Mizuho Kawate, Keisuke Nishimura, Kenta Misaki, Yumiko Nobuhara, Takashi Nakazawa, Saori Hatachi, Goh Tsuji, Akio Morinobu, Shunichi Kumagai

  The objective of the study is to develop genetic and clinical prediction models for the efficacy and hepatotoxicity of methotrexate (MTX) in patients with rheumatoid arthritis (RA). Among RA patients treated with MTX, 1966 polymorphisms of 246 enzymes/transporters relevant to pharmacokinetics and pharmacodynamics were measured by the Drug Metabolism Enzymes and Transporters (DMET) microarray and direct sequencing, and clinical variables at baseline were collected. For efficacy, response criteria of the European League Against Rheumatism were used to classify patients as responders or non-responders. Hepatotoxicity was defined as elevations of aspartate aminotransferase or alanine aminotransferase ≥1.5 times the reference range upper limit. Among 166 patients, a genetic prediction model for efficacy using seven polymorphisms showed the area under the receiver operating characteristic curve (AUC) was 0.822, with 74.3% sensitivity and 76.8% specificity. A combined genetic and clinical model indicated the AUC was 0.844, with 81.5% sensitivity and 76.9% specificity. By incorporating clinical variables into the genetic model, the overall category-free net reclassification improvement (NRI) was 0.663 (P < 0.0001) and the overall integrated discrimination improvement (IDI) was 0.083 (P = 0.0009). For hepatotoxicity, a genetic prediction model using seven polymorphisms showed the AUC was 0.783 with 70.0% sensitivity and 80.0% specificity, while the combined model indicated the AUC was 0.906 with 85.1% sensitivity and 87.8% specificity (overall category-free NRI: 1.002, P < 0.0001; overall IDI: 0.254, P < 0.0001). Our genetic and clinical models demonstrated moderate diagnostic accuracy for MTX efficacy and high accuracy for hepatotoxicity. These findings should, however, be validated and interpreted with a caution until external validation.

  03 Dec. 2019, The pharmacogenomics journal, English, International magazine


• IgG4関連疾患の臨床所見と顎下腺超音波shear wave elastographyの関連

  西村 啓佑, 佐原 朗子, 水川 薫, 門場 啓一郎, 吉田 知宏, 脇 大輔, 村部 浩之, 横田 敏彦

  (一社)日本臨床免疫学会, Oct. 2019, 日本臨床免疫学会総会プログラム・抄録集, 47回, 135 - 135, Japanese


• 下肢筋血管炎を伴う全身性エリテマトーデスの2例

  吉田 知宏, 西村 啓佑, 田中 望美, 松本 和也, 門場 啓一郎, 脇 大輔, 村部 浩之, 横田 敏彦

  (一社)日本臨床免疫学会, Oct. 2019, 日本臨床免疫学会総会プログラム・抄録集, 47回, 138 - 138, Japanese


• 下肢筋血管炎による下腿浮腫・腫脹を呈した全身性エリテマトーデス・抗リン脂質抗体症候群の1例

  水川 薫, 西村 啓佑, 門場 啓一郎, 向山 宙希, 吉田 知宏, 脇 大輔, 村部 浩之, 横田 敏彦

  (一社)日本臨床リウマチ学会, Sep. 2019, 臨床リウマチ, 31(3) (3), 233 - 238, Japanese


• SLE(臨床)-1 全身性エリテマトーデスの肺病変に関する検討

  水川 薫, 西村 啓佑, 門場 啓一郎, 向山 宙希, 吉田 知宏, 脇 大輔, 横田 敏彦

  (一社)日本リウマチ学会, Mar. 2019, 日本リウマチ学会総会・学術集会プログラム・抄録集, 63回, 474 - 474, Japanese


• 血管炎(ANCA関連血管炎)-4 好酸球性多発血管炎性肉芽腫症の長期予後に関する検討

  向山 宙希, 西村 啓佑, 水川 薫, 門場 啓一郎, 吉田 知宏, 脇 大輔, 横田 敏彦

  (一社)日本リウマチ学会, Mar. 2019, 日本リウマチ学会総会・学術集会プログラム・抄録集, 63回, 532 - 532, Japanese


• 関節リウマチの関節外病変 間質リウマチに合併した間質性肺炎の治療内容と予後に関する検討

  門場 啓一郎, 西村 啓佑, 水川 薫, 向山 宙希, 吉田 知宏, 脇 大輔, 横田 敏彦

  (一社)日本リウマチ学会, Mar. 2019, 日本リウマチ学会総会・学術集会プログラム・抄録集, 63回, 536 - 536, Japanese


• リウマチ性疾患と感染症-2 無症候性細菌尿を伴うリウマチ性疾患患者における尿路感染症発症リスクの検討

  吉田 知宏, 西村 啓佑, 水川 薫, 門場 啓一郎, 向山 宙希, 脇 大輔, 横田 敏彦

  (一社)日本リウマチ学会, Mar. 2019, 日本リウマチ学会総会・学術集会プログラム・抄録集, 63回, 563 - 563, Japanese


• SLEに合併したマクロファージ活性化症候群(MAS)と成人スティル病に合併したMASの臨床的な相違

  脇 大輔, 西村 啓佑, 水川 薫, 門場 啓一郎, 向山 宙希, 吉田 知宏, 横田 敏彦

  (一社)日本リウマチ学会, Mar. 2019, 日本リウマチ学会総会・学術集会プログラム・抄録集, 63回, 645 - 645, Japanese


• 分類不能型結合組織病に合併した血管内大細胞型B細胞性リンパ腫(Intravascular Large B-Cell Lymphoma with Undifferentiated Connective Tissue Disease)

  川先 孝幸, 西村 啓佑

  (公財)大原記念倉敷中央医療機構倉敷中央病院, Mar. 2019, 倉敷中央病院年報, 81, 49 - 54, English


• IgG4関連疾患の顎下腺病変における超音波shear wave elastographyの有用性

  西村 啓佑, 門場 啓一郎, 向山 宙希, 脇 大輔, 横田 敏彦

  (一社)日本臨床免疫学会, Nov. 2018, 日本臨床免疫学会総会プログラム・抄録集, 46回, 126 - 126, Japanese


• ステロイド大量療法を要したリウマチ性疾患患者におけるデノスマブの骨折予防効果の検討

  門場 啓一郎, 西村 啓佑, 向山 宙希, 齋藤 林太郎, 脇 大輔, 横田 敏彦

  (一社)日本臨床免疫学会, Nov. 2018, 日本臨床免疫学会総会プログラム・抄録集, 46回, 136 - 136, Japanese


• ANCA関連血管炎に対する血漿交換療法の有用性

  西村 啓佑, 脇 大輔, 門場 啓一郎, 向山 宙希, 横田 敏彦

  (一社)日本アフェレシス学会, Oct. 2018, 日本アフェレシス学会雑誌, 37(Suppl.) (Suppl.), 167 - 167, Japanese


• 血漿交換療法の併用により救命し得た顕微鏡的多発血管炎に合併した急速進行性糸球体腎炎の1例

  時岡 孝平, 中村 優理, 永本 匠, 西村 啓佑, 横田 敏彦

  (公財)大原記念倉敷中央医療機構倉敷中央病院, Mar. 2018, 倉敷中央病院年報, 80, 149 - 154, Japanese


• リウマチ性疾患の合併症(感染症以外・アミロイドーシス・その他)1:悪性腫瘍・骨粗鬆症 当科におけるM蛋白陽性患者の臨床的特徴の検討

  門場 啓一郎, 西村 啓佑, 向山 宙希, 齋藤 林太郎, 脇 大輔, 横田 敏彦

  (一社)日本リウマチ学会, Mar. 2018, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回, 440 - 440, Japanese


• SLE・抗リン脂質抗体症候群2 当院におけるループス腎炎(LN)64例の検討

  齋藤 林太郎, 西村 啓佑, 門場 啓一郎, 向山 宙希, 脇 大輔, 横田 敏彦

  (一社)日本リウマチ学会, Mar. 2018, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回, 446 - 446, Japanese


• 血管炎2:大型血管炎の臨床研究 20例の巨細胞性動脈炎に対する側頭動脈エコーのフォローアップに関する検討

  向山 宙希, 西村 啓佑, 門場 啓一郎, 齋藤 林太郎, 脇 大輔, 横田 敏彦

  (一社)日本リウマチ学会, Mar. 2018, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回, 457 - 457, Japanese


• 血管炎4:ANCA関連血管炎の臨床研究(アウトカム) 高齢発症のANCA関連血管炎患者に対し定型的な免疫抑制療法(conventional imuunosuppressive therapy)を行うことによる潜在的なリスクの検討

  脇 大輔, 門場 啓一郎, 向山 宙希, 齋藤 林太郎, 西村 啓佑, 横田 敏彦

  (一社)日本リウマチ学会, Mar. 2018, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回, 523 - 523, Japanese


• 薬剤誘発性ループスとの鑑別を要したSLE合併バセドウ病の1例

  伊藤 慶彦, 岡本 健太郎, 川島 彰透, 天野 綾, 脇 大輔, 浜松 圭太, 西村 啓佑, 岡崎 恭子, 西澤 衡, 村部 浩之, 横田 敏彦

  (一社)日本内分泌学会, Dec. 2017, 日本内分泌学会雑誌, 93(3) (3), 951 - 951, Japanese


• 膜性腎症を合併した抗SRP抗体陽性多発性筋炎の一例

  向山 宙希, 西村 啓佑, 門場 啓一郎, 齋藤 林太郎, 脇 大輔, 横田 敏彦

  (一社)日本臨床免疫学会, Aug. 2017, 日本臨床免疫学会会誌, 40(4) (4), 301 - 301, Japanese


• THE CLINICAL FEATURES OF 223 BEHCET'S DISEASE PATIENTS IN JAPAN

  R. Saito, K. Nishimura, H. Mukoyama, Y. Nakamura, T. Nagamoto, K. Akashi, A. Onishi, Y. Kogata, J. Saegusa, A. Morinobu, T. Yokota

  Jun. 2017, ANNALS OF THE RHEUMATIC DISEASES, 76, 422 - 422, English

  Summary international conference


• 血管炎 ANCA関連血管炎に伴う肺胞出血は予後不良である

  永本 匠, 向山 宙希, 齋藤 林太郎, 中村 優理, 西村 啓佑, 横田 敏彦

  (一社)日本リウマチ学会, Mar. 2017, 日本リウマチ学会総会・学術集会プログラム・抄録集, 61回, 441 - 441, Japanese


• ベーチェット病 ベーチェット病223例の臨床的特徴

  齋藤 林太郎, 西村 啓佑, 向山 宙希, 中村 優理, 永本 匠, 明石 健吾, 大西 輝, 古形 芳則, 三枝 淳, 森信 暁雄, 横田 敏彦

  (一社)日本リウマチ学会, Mar. 2017, 日本リウマチ学会総会・学術集会プログラム・抄録集, 61回, 444 - 444, Japanese


• 血管炎 下肢の筋血管炎・筋膜炎28症例の臨床的特徴

  向山 宙希, 西村 啓佑, 齋藤 林太郎, 中村 優理, 永本 匠, 横田 敏彦

  (一社)日本リウマチ学会, Mar. 2017, 日本リウマチ学会総会・学術集会プログラム・抄録集, 61回, 491 - 491, Japanese


• 骨粗鬆症と骨代謝/変形性関節症・軟骨 ステロイド骨粗鬆症(GIO)に対するデノスマブの有効性 2年間の使用成績

  明石 健吾, 西村 啓佑, 蔭山 豪一, 市川 晋也, 白井 太一朗, 山本 譲, 一瀬 良英, 山田 啓貴, 仲 郁子, 津田 耕作, 脇 大輔, 岡野 隆一, 高橋 宗史, 上田 洋, 千藤 荘, 大西 輝, 古形 芳則, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2017, 日本リウマチ学会総会・学術集会プログラム・抄録集, 61回, 545 - 545, Japanese


• リウマチ性疾患の合併症 当院におけるリウマチ性疾患治療中のサイトメガロウイルス感染症の検討

  中村 優理, 向山 宙希, 齋藤 林太郎, 永本 匠, 西村 啓佑, 横田 敏彦

  (一社)日本リウマチ学会, Mar. 2017, 日本リウマチ学会総会・学術集会プログラム・抄録集, 61回, 546 - 546, Japanese


• Dual Effect of 3-Bromopyruvate on Both Th17 and Treg Cell Differentiation and Dendritic Cell Activation Ameliorates Autoimmune Arthritis in Mice

  Takaichi Okano, Jun Saegusa, Keisuke Nishimura, Yo Ueda, Sho Sendo, Soshi Takahashi, Kengo Akashi, Akira Onishi, Akio Morinobu

  Oct. 2016, ARTHRITIS & RHEUMATOLOGY, 68, English

  Summary international conference


• SKGマウス肺病変の進展に伴って増加するCD11b+Gr1 dimcellはGM-CSFによって誘導される

  千藤 荘, 一瀬 良英, 山田 啓貴, 津田 耕作, 仲 郁子, 岡野 隆一, 高橋 宗史, 西村 啓佑, 上田 洋, 明石 健吾, 大西 輝, 古形 芳則, 三枝 淳, 森信 暁雄

  (一社)日本臨床免疫学会, Aug. 2016, 日本臨床免疫学会会誌, 39(4) (4), 410 - 410, Japanese


• 四肢の筋力低下を認め、筋生検で筋サルコイドーシスの診断となった1例

  永本 匠, 向山 宙希, 齋藤 林太郎, 中村 優理, 西村 啓佑, 横田 敏彦

  (一社)日本臨床免疫学会, Aug. 2016, 日本臨床免疫学会会誌, 39(4) (4), 431 - 431, Japanese


• リウマチ性疾患の基礎研究 SKGマウス肺病変の進展に伴って増加するCD11b+Gr1dim cellはGM-CSFによって誘導される

  千藤 荘, 仲 郁子, 津田 耕作, 岡野 隆一, 西田 美和, 明石 健吾, 高橋 宗史, 上田 洋, 西村 啓佑, 大西 輝, 古形 芳則, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2016, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 344 - 344, Japanese


• ベーチェット病 特殊型ベーチェット病に対するTNF阻害剤の有効性

  西村 啓佑, 津田 耕作, 仲 郁子, 岡野 隆一, 明石 健吾, 高橋 宗史, 西田 美和, 上田 洋, 千藤 荘, 大西 輝, 古形 芳則, 蔭山 豪一, 三枝 淳, 河野 誠司, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2016, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 361 - 361, Japanese


• 多発性筋炎・皮膚筋炎 間質性肺疾患(ILD)を合併する炎症性筋疾患(IIM)、特にClinically amyopathic dermatomyositis(CADM)における治療前KL-6/SP-D値の検討

  明石 健吾, 西村 啓佑, 大西 輝, 古形 芳則, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2016, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 436 - 436, Japanese


• 関節リウマチの治療評価と予測 疼痛評価VASが高い患者の健康状態全般評価VASは過小申告されていることがある(ROCKoコホート研究から)

  蔭山 豪一, 大西 輝, 上田 洋, 仲 郁子, 津田 耕作, 岡野 隆一, 高橋 宗史, 西田 美和, 明石 健吾, 西村 啓佑, 千藤 荘, 古形 芳則, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2016, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 447 - 447, Japanese


• 関節リウマチの治療 QOL 治療目標に到達した関節リウマチ患者の主観的幸福度は、一般的な日本人より高い(ROCKoコホート研究から)

  蔭山 豪一, 大西 輝, 上田 洋, 仲 郁子, 津田 耕作, 岡野 隆一, 高橋 宗史, 西田 美和, 明石 健吾, 西村 啓佑, 千藤 荘, 古形 芳則, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2016, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 456 - 456, Japanese


• リウマチ性疾患の疫学 関節リウマチ患者における社会経済的要因が疾患活動性、日常生活動作に与える影響の検討(ROCKoコホート研究から)

  大西 輝, 蔭山 豪一, 上田 洋, 津田 耕作, 仲 郁子, 岡野 隆一, 明石 健吾, 西村 啓佑, 高橋 宗史, 西田 美和, 千藤 荘, 古形 芳則, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2016, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 468 - 468, Japanese


• 多発性筋炎、強皮症合併のOverlap症候群に肺リンパ増殖性疾患を合併した小児の一例

  亀井 優衣子, 西村 啓佑, 脇 大輔, 一瀬 良英, 山田 啓貴, 大西 輝, 古形 芳則, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2016, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 599 - 599, Japanese


• シクロフォスファミドが著効したシェーグレン症候群に伴う蛋白漏出性胃腸症の一例

  一瀬 良英, 古形 芳則, 亀井 優衣子, 山田 啓貴, 脇 大輔, 津田 耕作, 西村 啓佑, 大西 輝, 梅田 良祐, 辻 剛, 森信 暁雄, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2016, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 668 - 668, Japanese


• トファシチニブは骨髄由来サプレッサー細胞に作用して治療効果を発揮する

  西村啓佑, Saegusa Jun, Morinobu Akio

  (有)科学評論社, Jan. 2016, リウマチ科, 55(1号) (1号), 115 - 119, Japanese

  [Invited]

  Introduction commerce magazine


• Taurine As a Biomarker for Prediction of Response to Biologic Therapy in Rheumatoid Arthritis

  Soshi Takahashi, Jun Saegusa, Ikuko Naka, Kosaku Tsuda, Takaichi Okano, Kengo Akashi, Miwa Nishida, Keisuke Nishimura, Sho Sendo, Yo Ueda, Akira Onishi, Yoshinori Kogata, Goichi Kageyama, Akio Morinobu

  Oct. 2015, ARTHRITIS & RHEUMATOLOGY, 67, English

  Summary international conference


• High Serum IgG4 Concentration Is a Risk Factor for Relapse in IgG4-Related Disease

  Sho Sendo, Jun Saegusa, Akira Onishi, Ikuko Naka, Kosaku Tsuda, Takaichi Okano, Kengo Akashi, Soshi Takahashi, Miwa Nishida, Keisuke Nishimura, Yo Ueda, Yoshinori Kogata, Goichi Kageyama, Goh Tsuji, Shunichi Kumagai, Akio Morinobu

  Oct. 2015, ARTHRITIS & RHEUMATOLOGY, 67, English

  Summary international conference


• シェーグレン症候群患者の睡眠評価とそれに影響を及ぼす因子の検討

  津田 耕作, 明石 健吾, 西村 啓佑, 千藤 荘, 三枝 淳, 森信 暁雄

  (一社)日本臨床免疫学会, Sep. 2015, 日本臨床免疫学会会誌, 38(4) (4), 350 - 350, Japanese


• 脊椎関節炎57例の臨床的検討

  千藤 荘, 津田 耕作, 明石 健吾, 西村 啓佑, 三枝 淳, 森信 暁雄

  (一社)日本臨床免疫学会, Sep. 2015, 日本臨床免疫学会会誌, 38(4) (4), 353 - 353, Japanese


• ベーチェット病151例の臨床的特徴

  西村 啓佑, 津田 耕作, 明石 健吾, 千藤 荘, 三枝 淳, 森信 暁雄

  (一社)日本臨床免疫学会, Sep. 2015, 日本臨床免疫学会会誌, 38(4) (4), 354 - 354, Japanese


• 関節リウマチの病因・病態 血清メタボローム解析による関節リウマチの代謝プロファイルの解明および各種生物学的製剤投与後の代謝変動の解析

  高橋 宗史, 三枝 淳, 岡野 隆一, 千藤 荘, 明石 健吾, 西田 美和, 西村 啓佑, 古形 芳則, 蔭山 豪一, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2015, 日本リウマチ学会総会・学術集会プログラム・抄録集, 59回, 328 - 328, Japanese


• リウマチ性疾患の基礎研究 JAK1/3阻害がMyeloid-derived suppressor cellを誘導し、SKGマウス関節炎を抑制する

  西村 啓佑, 三枝 淳, 明石 健吾, 岡野 隆一, 西田 美和, 高橋 宗史, 千藤 荘, 大西 輝, 古形 芳則, 蔭山 豪一, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2015, 日本リウマチ学会総会・学術集会プログラム・抄録集, 59回, 336 - 336, Japanese


• その他の膠原病 脊椎関節炎51例の臨床的検討

  千葉 荘, 亀井 優衣子, 脇 大輔, 仲 郁子, 津田 耕作, 岡野 隆一, 明石 健吾, 西田 美和, 西村 啓佑, 高橋 宗史, 上田 洋, 大西 輝, 古形 芳則, 蔭山 豪一, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2015, 日本リウマチ学会総会・学術集会プログラム・抄録集, 59回, 369 - 369, Japanese


• Immediate Early Response Gene X-1(IEX-1)は関節リウマチ滑膜細胞(RA-SF)に発現し、アポトーシスを誘導し、サイトカイン産生を調節する

  森信 暁雄, 西村 啓佑, 蔭山 豪一, 三枝 淳, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2015, 日本リウマチ学会総会・学術集会プログラム・抄録集, 59回, 471 - 471, Japanese


• 原発性シェーグレン患者における睡眠障害の検討

  津田 耕作, 蔭山 豪一, 亀井 優衣子, 仲 郁子, 岡野 隆一, 高橋 宗史, 西田 美和, 明石 健吾, 西村 啓佑, 千藤 荘, 上田 洋, 大西 輝, 古形 芳則, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2015, 日本リウマチ学会総会・学術集会プログラム・抄録集, 59回, 657 - 657, Japanese


• 【自己免疫疾患の免疫学的治療新戦略】 Myeloid-derived suppressor cellの誘導による自己免疫疾患の治療

  西村 啓佑, Saegusa Jun, Morinobu Akio

  科学評論社, Nov. 2014, 臨床免疫・アレルギー科, 62(5号) (5号), 481 - 484, Japanese

  [Invited]

  Introduction commerce magazine


• Immediate Early Response Gene X-1(IEX-1)は関節リウマチ滑膜細胞(RA-SF)に発現し、アポトーシスを誘導し、サイトカイン産生を調節する

  森信 暁雄, 田中 姿乃, 西村 啓佑, 蔭山 豪一, 三枝 淳, 熊谷 俊一

  (一社)日本臨床免疫学会, Aug. 2014, 日本臨床免疫学会会誌, 37(4) (4), 345 - 345, Japanese


• 当院における炎症性筋疾患(IIM)88例の治療経験

  明石 健吾, 亀井 優衣子, 脇 大輔, 仲 郁子, 津田 耕作, 岡野 隆一, 西田 美和, 西村 啓佑, 高橋 宗史, 上田 洋, 千藤 荘, 杉山 大典, 古形 芳則, 蔭山 豪一, 三枝 淳, 熊谷 俊一, 森信 暁雄

  (一社)日本臨床免疫学会, Aug. 2014, 日本臨床免疫学会会誌, 37(4) (4), 375 - 375, Japanese


• 当院におけるIgG4関連疾患25例の再燃リスクについての検討

  千藤 荘, 亀井 優衣子, 脇 大輔, 仲 郁子, 津田 耕作, 岡野 隆一, 明石 健吾, 西田 美和, 西村 啓佑, 高橋 宗史, 上田 洋, 大西 輝, 古形 芳則, 蔭山 豪一, 三枝 淳, 森信 暁雄

  (一社)日本臨床免疫学会, Aug. 2014, 日本臨床免疫学会会誌, 37(4) (4), 379 - 379, Japanese


• IgG4関連疾患 当科におけるIgG4関連疾患が疑われた26例の臨床的検討(再燃例について)

  山本 譲, 千藤 荘, 津田 耕作, 岡野 隆一, 明石 健吾, 高橋 宗史, 西田 美和, 西村 啓佑, 古形 芳則, 蔭山 豪一, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2014, 日本リウマチ学会総会・学術集会プログラム・抄録集, 58回, 314 - 314, Japanese


• リウマチ性疾患の基礎研究 TofacitinibはMyeloid-derived suppressor cellを誘導し、SKGマウス関節炎を抑制する

  西村 啓佑, 三枝 淳, 明石 健吾, 西田 美和, 高橋 宗史, 古形 芳則, 蔭山 豪一, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2014, 日本リウマチ学会総会・学術集会プログラム・抄録集, 58回, 406 - 406, Japanese


• 多発性筋炎・皮膚筋炎 当院における炎症性筋疾患(IIM)88例の治療経験

  明石 健吾, 山本 譲, 津田 耕作, 岡野 隆一, 高橋 宗史, 西田 美和, 西村 啓佑, 千藤 荘, 杉山 大典, 古形 芳則, 蔭山 豪一, 三枝 淳, 熊谷 俊一, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2014, 日本リウマチ学会総会・学術集会プログラム・抄録集, 58回, 437 - 437, Japanese


• 心外膜炎で発症したIgG4関連疾患の一例

  千藤 荘, 山本 譲, 津田 耕作, 岡野 隆一, 明石 健吾, 高橋 宗史, 西田 美和, 西村 啓佑, 古形 芳則, 蔭山 豪一, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2014, 日本リウマチ学会総会・学術集会プログラム・抄録集, 58回, 559 - 559, Japanese


• シェーグレン症候群患者の唾液メタボロミクス

  蔭山 豪一, 三枝 淳, 高橋 宗史, 西田 美和, 山本 譲, 津田 耕作, 岡野 隆一, 明石 健吾, 西村 啓佑, 千藤 荘, 古形 芳則, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2014, 日本リウマチ学会総会・学術集会プログラム・抄録集, 58回, 715 - 715, Japanese


• Laboratory Practice 免疫・生化学 炎症マーカーの使い分け

  西村 啓佑, 古形 芳則, Morinobu Akio

  (株)医学書院, Dec. 2013, 検査と技術, 41(13号) (13号), 1256 - 1258, Japanese

  [Invited]

  Introduction commerce magazine


• Clinical Features Of 127 Patients With Behcet's Disease In Japan

  Keisuke Nishimura, Jun Saegusa, Sho Sendo, Yoshinori Kogata, Goichi Kageyama, Seiji Kawano, Shunichi Kumagai, Akio Morinobu

  Oct. 2013, ARTHRITIS AND RHEUMATISM, 65, S1115 - S1115, English

  Summary international conference


• CD45RA-Foxp3high制御性T細胞は、RA患者末梢血中のCD27+CD28+セントラルメモリーT細胞分画で減少している

  三枝 淳, 松木 郁親, 西村 啓佑, 熊谷 俊一, 森信 暁雄

  (一社)日本臨床免疫学会, Oct. 2013, 日本臨床免疫学会会誌, 36(5) (5), 367 - 367, Japanese


• TofacitinibはMyeloid-derived suppressor cellを誘導し、マウス関節炎を抑制する

  西村 啓佑, 三枝 淳, 松木 郁親, 田中 姿乃, 明石 健吾, 森信 暁雄

  (一社)日本臨床免疫学会, Oct. 2013, 日本臨床免疫学会会誌, 36(5) (5), 380 - 380, Japanese


• ベーチェット病113例の臨床的特徴

  西村 啓佑, 津田 耕作, 岡野 隆一, 高橋 宗史, 西田 美和, 明石 健吾, 大西 輝, 栗本 千代, 古形 芳則, 蔭山 豪一, 三枝 淳, 杉本 健, 河野 誠司, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2013, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 57回・22回, 535 - 535, Japanese


• RA末梢血及び関節液中の制御性/炎症性CD4陽性T細胞サブセットの解析

  松木 郁親, 三枝 淳, 宮本 佳昭, 三崎 健太, 西村 啓佑, 河野 誠司, 熊谷 俊一, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2013, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 57回・22回, 555 - 555, Japanese


• 肥厚性硬膜炎を合併した肉芽腫性多発血管炎(GPA)の治療中に髄液漏を来した1例

  永本 匠, 西田 美和, 明石 健吾, 西村 啓佑, 津田 耕作, 岡野 隆一, 高橋 宗史, 大西 輝, 古形 芳則, 蔭山 豪一, 三枝 淳, 杉本 健, 河野 誠司, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2013, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 57回・22回, 599 - 599, Japanese


• リツキシマブ、クリオフィルトレーションを含む集学的治療にて治療しえた難治性クリオグロブリン血管炎の1例

  津田 耕作, 蔭山 豪一, 岡野 隆一, 高橋 宗史, 明石 健吾, 西田 美和, 西村 啓佑, 大西 輝, 古形 芳則, 三枝 淳, 杉本 健, 河野 誠司, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2013, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 57回・22回, 673 - 673, Japanese


• 感染症と自己免疫疾患(2) 膠原病患者の最近感染症診断におけるプロカルシトニンの有用性について(メタアナリシス)

  古形 芳則, 杉山 大典, 大西 輝, 仲 郁子, 津田 耕作, 西村 啓佑, 三崎 健太, 蔭山 豪一, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2012, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 56回・21回, 335 - 335, Japanese


• 増殖性ループス腎炎の寛解導入療法におけるミコフェノール酸モフェチルとシクロホスファミド間歇静注療法の有用性と安全性の検討

  大西 輝, 杉山 大典, 津田 耕作, 仲 郁子, 西村 啓佑, 三崎 健太, 栗本 千代, 古形 芳則, 辻 剛, 蔭山 豪一, 三枝 淳, 杉本 健, 河野 誠司, 熊谷 俊一, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2012, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 56回・21回, 524 - 524, Japanese


• アダリムマブ(ADA)投与後、抗糸球体基底膜(GBM)抗体の陽転化を認めた顕微鏡的多発血管炎の1例

  仲 郁子, 三崎 健太, 西村 啓佑, 津田 耕作, 大西 輝, 古形 芳則, 蔭山 豪一, 三枝 淳, 河野 誠司, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2012, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 56回・21回, 541 - 541, Japanese


• 真性多血症、巣状糸球体硬化症を合併した大動脈炎症候群の1例

  山田 啓貴, 西村 啓佑, 仲 郁子, 津田 耕作, 大西 輝, 三崎 健太, 古形 芳則, 蔭山 豪一, 三枝 淳, 河野 誠司, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2012, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 56回・21回, 615 - 615, Japanese


• 腸管病変と血管病変を合併したベーチェット病の3例

  西村 啓佑, 仲 郁子, 津田 耕作, 大西 輝, 三崎 健太, 古形 芳則, 蔭山 豪一, 三枝 淳, 杉本 健, 河野 誠司, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2012, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 56回・21回, 671 - 671, Japanese


• 強膜炎を契機に高安動脈炎の診断に至った不明熱の1例

  三島 祥平, 藤田 俊一, 西村 啓佑, 三浦 菜津子, 中澤 隆, 横田 敏彦

  (公財)大原記念倉敷中央医療機構倉敷中央病院, Mar. 2012, 倉敷中央病院年報, 74, 239 - 243, Japanese


• A Meta-Analysis: Diagnostic Accuracy of Serum Procalcitonin Concentrations for Detecting Systemic Bacterial Infection In Patients with Rheumatic Diseases.

  Yoshinori Kogata, Daisuke Sugiyama, Akira Onishi, Ikuko Naka, Kosaku Tsuda, Keisuke Nishimura, Kenta Misaki, Goichi Kageyama, Akio Morinobu

  Oct. 2011, ARTHRITIS AND RHEUMATISM, 63(10) (10), S412 - S412, English

  Summary international conference


• アダリムマブ投与後、抗糸球体基底膜抗体の陽転化を認めた顕微鏡的多発血管炎の1例

  西村 啓佑, 仲 郁子, 三崎 健太, 津田 耕作, 大西 輝, 古形 芳則, 蔭山 豪一, 三枝 淳, 杉本 健, 河野 誠司, 熊谷 俊一, 森信 暁雄

  (一社)日本臨床免疫学会, Aug. 2011, 日本臨床免疫学会会誌, 34(4) (4), 312 - 312, Japanese


• リウマチ性疾患の画像 寛解維持予測因子としての超音波画像的寛解の意義について

  西村 啓佑, 中澤 隆, 藤田 俊一, 三浦 菜津子, 森信 暁雄, 杉山 大典, 熊谷 俊一, 横田 敏彦

  (一社)日本リウマチ学会, Jun. 2011, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 55回・20回, 297 - 297, Japanese


• アダリムマブ アダリムマブ投与RA患者での抗アダリムマブ抗体と治療効果の関係(多施設共同研究)

  辻 剛, 河野 誠司, 森信 暁雄, 三枝 淳, 杉山 大典, 八木田 正人, 籏智 さおり, 波内 俊三, 信原 由実子, 中澤 隆, 西村 啓佑, 中村 知子, 千藤 荘, 熊谷 俊一

  (一社)日本リウマチ学会, Jun. 2011, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 55回・20回, 300 - 300, Japanese


• 血管炎症候群におけるPTX3測定の有用性についての検討

  藤田 俊一, 中澤 隆, 西村 啓佑, 三浦 菜津子, 横田 敏彦

  (一社)日本リウマチ学会, Jun. 2011, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 55回・20回, 514 - 514, Japanese


• 側頭動脈炎における生検の有用性

  三浦 菜津子, 中澤 隆, 藤田 俊一, 西村 啓佑, 横田 敏彦

  (一社)日本リウマチ学会, Jun. 2011, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 55回・20回, 620 - 620, Japanese


• Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome(RS3PE症候群)として治療経過中にびまん性大細胞型B細胞リンパ腫(DLBCL)と診断された1例

  北口 耕輔, 新井 康之, 城 友泰, 松山 文男, 上田 恭典, 西村 啓佑

  (公財)大原記念倉敷中央医療機構倉敷中央病院, Mar. 2011, 倉敷中央病院年報, 73, 233 - 238, Japanese


• 筋生検で誘発された線維筋痛症の1例

  高瀬 真知, 西村 啓佑, 中澤 隆

  (公財)大原記念倉敷中央医療機構倉敷中央病院, Mar. 2011, 倉敷中央病院年報, 73, 245 - 249, Japanese


• タクロリムス 関節リウマチ患者におけるメトトレキサート関連リンパ増殖性疾患の検討

  綾野 雅宏, 中澤 隆, 西村 啓佑, 西川 あゆみ, 杉山 大典, 熊谷 俊一, 横田 敏彦

  (一社)日本リウマチ学会, Mar. 2010, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 54回・19回, 514 - 514, Japanese


• 血管炎・APS 四肢限局型血管炎の10例

  西川 あゆみ, 中澤 隆, 綾野 雅宏, 西村 啓佑, 横田 敏彦

  (一社)日本リウマチ学会, Mar. 2010, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 54回・19回, 545 - 545, Japanese


• シェーグレン症候群を合併した抗RNP抗体陽性の強皮症に生じた強皮症腎クリーゼの1例

  西村 啓佑, 中澤 隆, 西川 あゆみ, 綾野 雅宏, 横田 敏彦

  (一社)日本リウマチ学会, Mar. 2010, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 54回・19回, 674 - 674, Japanese


• 超音波検査(MSK-US)による関節リウマチ(RA)の画像的寛解(IR)判定の検討

  中澤 隆, 綾野 雅宏, 西川 あゆみ, 西村 啓佑, 横田 敏彦

  (一社)日本リウマチ学会, Mar. 2010, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 54回・19回, 732 - 732, Japanese


• 上咽頭癌に対する放射線治療後に下垂体機能低下症をきたした1例

  竹島 健, 西村 啓佑, 西川 あゆみ, 綾野 雅宏, 桑原 一宏, 中澤 隆, 村部 浩之, 村上 典彦, 横田 敏彦, 日下 昌平

  (株)自然科学社, Oct. 2009, 医学と薬学, 62(4) (4), 647 - 647, Japanese


• 急性脱随性末梢神経障害(AIDP)と眼筋型重症筋無力症(眼筋型MG)を呈したNPSLEの一例

  西村 啓佑, 宮川 佳澄, 藤田 昌昭, 三崎 健太, 笠木 伸平, 林 宏樹, 辻 剛, 三枝 淳, 杉本 健, 河野 誠司, 森信 暁雄, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2009, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 53回・18回, 367 - 367, Japanese

• 日本臨床リウマチ学会


• 日本アフェレシス学会


• 日本炎症・再生医学会


• 日本免疫学会


• 日本臨床免疫学会


• 日本リウマチ学会


• 日本内科学会

• 好中球に着眼したシェーグレン症候群の新規病理分類提案と治療薬探索

  後藤 育子, 西村 啓佑, 重岡 学, 木本 明, 明石 昌也, 明石 健吾, 筧 康正

  日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 01 Apr. 2023 - 31 Mar. 2026


• The fluctuation in subjective well-being of patients with early rheumatoid arthritis

  蔭山 豪一, 森信 暁雄, 三枝 淳, 籏智 さおり, 西村 啓佑

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Hyogo Prefectural Amagasaki General Medical Center, 01 Apr. 2020 - 31 Mar. 2024

  主観的幸福度とはどのくらい幸せかを本人の主観を元に測るものであり、自身への認知的評価と感情的喜びを表すとされている。主観的幸福度に健康状態が深く関連することは知られている。 今回、主観的幸福度が大きく変動すると考えられる早期関節リウマチ（RA）患者を対象として、健康状態と主観的幸福度の変動の研究を、多施設前向き研究で行う。 本研究により、疾患を治療することが患者の幸福にどこまで反映されるのか？医療において患者の幸福に最も重要な因子は何か？患者負担のもとで、難治性疾患の患者に高額な薬剤を使用することは、本当に患者の幸福になるのか？などを解析する。 さらに、診療の質の評価として、患者の主観的幸福度を使用することの妥当性を検討し、主観的幸福度を実臨床でのアウトカム指標として使用する基盤となる研究を目指す。


• Novel treatment of autoimmune diseases using myeloid-derived suppressor cell

  Nishimura Keisuke

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B), Grant-in-Aid for Young Scientists (B), Kobe University, 01 Apr. 2016 - 31 Mar. 2020

  Glutamine metabolism and the mechanistic mTOR pathway are activated cooperatively in the differentiation and activation of inflammatory immune cells. This study investigated how inhibiting both glutamine metabolism with DON and mTOR with rapamycin affects immune cells and the arthritis in a mouse model. We revealed that rapamycin and DON additively suppressed CD4+ T cell proliferation, and both of them inhibited Th17 cell differentiation. While DON inhibited the differentiation of dendritic cells and macrophages and facilitated that of Ly6G+ granulocytic (G)-MDSCs more strongly than did rapamycin, G-MDSCs treated with rapamycin but not DON suppressed CD4+ T cell proliferation in vitro. The combination of rapamycin and DON significantly suppressed the arthritis in SKG mice more strongly than did each monotherapy in vivo. The numbers of CD4+ T and Th17 cells in the spleen were lowest in mice treated with the combination therapy.